Related Experiment Videos
Evaluation of aztreonam in experimental bacterial meningitis and cerebritis
Abstract:
Aztreonam (SQ 26,776), a new monocyclic beta-lactam agent, was compared with ampicillin, ampicillin plus chloramphenicol, and gentamicin in rabbits with experimental meningitis induced by, respectively, ampicillin-susceptible Haemophilus influenzae, ampicillin-resistant H. influenzae, and Escherichia coli. Aztreonam was also compared with gentamicin in experimentally induced E. coli cerebritis in rats. Doses of the various agents were delivered that produced near-peak concentrations in serum comparable to those attained in humans on standard parenteral regimens. The percent penetration [( concentration in cerebrospinal fluid/concentration in serum] X 100) of aztreonam into purulent rabbit cerebrospinal fluid was 23% (versus 12, 27, and 21%, respectively, for ampicillin, chloramphenicol, and gentamicin). In experimental meningitis in vivo, aztreonam was more rapidly bactericidal than was ampicillin in ampicillin-susceptible H. influenzae meningitis, ampicillin or chloramphenicol in ampicillin-resistant H. influenzae meningitis, or gentamicin in E. coli meningitis. In the therapy of experimental cerebritis, the early stage of brain abscess formation, aztreonam reduced the numbers of E. coli in rat brain as rapidly as did gentamicin. Aztreonam deserves further evaluation in acute gram-negative bacterial infections of the central nervous system in both experimental animals and in humans.
Insights
Aztreonam demonstrated superior efficacy in treating experimental bacterial meningitis and cerebritis in animal models. This new monocyclic beta-lactam agent showed better penetration and faster bactericidal activity against key pathogens like Haemophilus influenzae and Escherichia coli.
Area of Science:
- Pharmacology
- Infectious Diseases
- Neuroscience
Background:
- Central nervous system (CNS) infections pose significant therapeutic challenges.
- Limited treatment options exist for meningitis and cerebritis caused by gram-negative bacteria.
- Novel antimicrobial agents with enhanced CNS penetration are needed.
Purpose of the Study:
- To evaluate the efficacy of aztreonam in experimental models of meningitis and cerebritis.
- To compare aztreonam's cerebrospinal fluid (CSF) penetration and bactericidal activity with existing antibiotics.
- To assess aztreonam's potential for treating gram-negative bacterial CNS infections.
Main Methods:
- Experimental meningitis induced in rabbits using ampicillin-susceptible and resistant Haemophilus influenzae, and Escherichia coli.
- Experimental cerebritis induced in rats using E. coli.
- Comparison of aztreonam with ampicillin, chloramphenicol, and gentamicin.
- Measurement of drug concentrations in serum and CSF to determine penetration.
- Assessment of bactericidal activity in vivo.
Main Results:
- Aztreonam exhibited superior penetration into purulent rabbit CSF (23%) compared to ampicillin (12%), chloramphenicol (27%), and gentamicin (21%).
- Aztreonam demonstrated more rapid bactericidal activity against H. influenzae and E. coli in experimental meningitis models than comparator agents.
- In experimental cerebritis, aztreonam reduced E. coli brain counts as effectively as gentamicin.
Conclusions:
- Aztreonam shows promising efficacy in treating experimental gram-negative bacterial meningitis and cerebritis.
- Its favorable CSF penetration and rapid bactericidal action support further investigation.
- Aztreonam warrants further evaluation for treating acute CNS infections in humans.